Litigation Details for Sanofi v. Sun Pharma Global FZE (N.D. Ill. 2014)

Sanofi v. Sun Pharma Global FZE (N.D. Ill. 2014)

Docket		Date Filed	2014-03-14
Court	District Court, N.D. Illinois	Date Terminated	2014-05-02
Cause	35:271 Patent Infringement	Assigned To	Ruben Castillo
Jury Demand	None	Referred To
Patents	7,323,493; 8,318,800; 8,410,167; 8,602,215
Link to Docket	External link to docket

Details for Sanofi v. Sun Pharma Global FZE (N.D. Ill. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-03-14				External link to document

Litigation summary and analysis for: Sanofi v. Sun Pharma Global FZE (N.D. Ill. 2014)

Last updated: May 26, 2026

Sanofi v. Sun Pharma Global FZE (1:14-cv-01844): Litigation Summary, Claims at Issue, and Paragraph IV/Orange Book Exposure

Executive summary: The docket 1:14-cv-01844 is a federal Hatch-Waxman patent infringement case filed by Sanofi against Sun Pharma Global FZE in the US District Court. The litigation record centers on Orange Book-listed patent(s) tied to Sanofi’s marketed drug(s) and Sun’s planned generic entry. The case posture, asserted claims, and whether any settlement resolved exclusivity/launch timing depend on the specific parties’ filings and court orders in the docket.

Outcome-ready view: Use the docket to extract (1) asserted patent numbers and claim ranges, (2) Sun’s ANDA submission/paragraph IV basis described in the pleadings, (3) Markman, claim construction outcomes, injunction/consent terms, and (4) final disposition (final judgment or settlement with stipulated dismissal). Without the docket’s underlying filings and orders text, litigation risk cannot be mapped to precise patents, deadlines, or launch calendars.

Case identifier: Sanofi v. Sun Pharma Global FZE, 1:14-cv-01844 (US District Court).

---

What patents are at issue in Sanofi v. Sun Pharma Global FZE 1:14-cv-01844?

Featured snippet (answer): The litigation involves one or more Orange Book-listed Sanofi patents asserted against Sun Pharma’s ANDA-based generic challenge, but the specific asserted patent numbers and claim lists are not identifiable from the case caption alone.

Typical Hatch-Waxman patent categories in these disputes

In Hatch-Waxman cases in this posture, Sanofi’s asserted estate typically falls into:

• Composition-of-matter patents for the active ingredient or drug substance
• Formulation patents (tablet composition, coating, particle engineering, excipients)
• Method-of-use patents (indications, dosing regimens, administration methods)
• Manufacturing/process patents (solid-state conversion, polymorph control, crystallization)

How to map the asserted claims to launch risk

The litigation’s practical impact depends on whether the asserted patents are:

• Core compound patents (highest barrier; usually block launch until expiration or settlement)
• Secondary formulation/process patents (often drive design-around risk)
• Method-of-use patents (often manageable if the generic uses a carve-out label design)

Actionable requirement: To quantify infringement risk and generic entry timelines, you need the complaint list of asserted patents and the answer with defenses describing Sun’s paragraph IV/other certifications.

---

What does Paragraph IV or AB-rated certification mean in Sanofi v. Sun Pharma Global FZE 1:14-cv-01844?

Featured snippet (answer): Sun’s filing likely included a Hatch-Waxman certification that ties the ANDA to the Orange Book patents asserted by Sanofi. The legal theory usually proceeds as a paragraph IV infringement case if Sun certified noninfringement/invalidity for at least one asserted patent.

Key certification pathways

• Paragraph IV (21 U.S.C. § 355(j)(2)(A)(vii)): Triggers the 30-month stay (subject to later outcomes).
• Paragraph III or II: Moves the stay and launch timing differently.
• AB substitution: May reduce or shift the need for label carve-outs.

Why certification type changes settlement leverage

• Paragraph IV cases typically create stronger leverage for the brand via the 30-month automatic stay and injunction pressure.
• If the case is driven by method-of-use patents, label carve-outs can reduce injunction threat.
• If the case centers on composition/formulation, design-around is more expensive and litigation risk stays higher.

---

When does Sanofi v. Sun Pharma Global FZE 1:14-cv-01844 affect exclusivity and generic launch timing?

Featured snippet (answer): The litigation’s impact is usually tied to the 30-month stay triggered by a paragraph IV ANDA certification and any subsequent court rulings or settlement dismissal timing. The exact timing requires the docket’s stay status events and any final order.

Exclusivity timelines that typically apply

Depending on the brand’s regulatory status:

• 5-year new chemical entity exclusivity or 3-year new clinical investigation exclusivity
• Orphan exclusivity (if applicable)
• Patent expiration dates that control ANDA approval timing
• 30-month stay expiration date after first-filing ANDA

Settlement scenarios that change “effective launch date”

Common settlement structures include:

• A stipulated dismissal after a payment and launch-date commitment
• A covenant not to sue until a specific date
• License terms for certain patent families
• Resolved “at-risk launch” triggers tied to future FDA approvals

---

Who are the parties and what is the litigation posture in 1:14-cv-01844?

Featured snippet (answer): Sanofi is the plaintiff; Sun Pharma Global FZE is the defendant. The posture and outcome are determined by the docket’s procedural events (motions to dismiss, answers, claim construction, summary judgment, trial, or settlement).

Procedural milestones that determine case value

• Complaint filing date and first service
• Answer and affirmative defenses (noninfringement, invalidity, unenforceability)
• Claim construction (Markman) schedule
• Summary judgment on infringement/invalidity
• Injunction motions and any consent terms
• Final judgment or stipulation of dismissal

---

What is the Orange Book status of Sanofi’s patents in this case?

Featured snippet (answer): The asserted patents should appear as Orange Book-listed drug patents with specific expiration dates and corresponding listed drug (RLD) details. The docket must be cross-referenced to the Orange Book patent list for exact numbers.

How Orange Book listings feed the infringement analysis

• If patents are listed for the same drug product and strength/form as the ANDA, infringement exposure is direct.
• If the ANDA’s formulation differs (different salt, strength, dosage form), exposure can shift to formulation-specific patents.

---

Which generic entry risks exist for Sun Pharma Global FZE under this litigation?

Featured snippet (answer): If Sun’s ANDA is not resolved by a settlement or a brand-favorable judgment, generic entry risks include injunction and damages exposure from final infringement findings.

Risk drivers

• Court construction of disputed claim terms
• Validity outcomes (anticipation/obviousness, lack of enablement, indefiniteness)
• Indirect infringement theories (method-of-use and induced infringement)
• Design-around viability for formulation claims

---

What did the court decide in Sanofi v. Sun Pharma Global FZE 1:14-cv-01844?

Featured snippet (answer): This cannot be determined from the docket identifier alone. Court decision content must be drawn from orders, judgments, and docket entries.

What you should extract from the record

• Final disposition: dismissed, settled, or judgment
• Whether claims were found: infringed or not
• Whether patents were held: invalid or not
• Any injunction: scope and duration
• Any stipulated dismissal: effective launch date and conditions

---

How strong is Sanofi’s patent estate in this dispute?

Featured snippet (answer): Strength depends on the number and type of asserted patents, the validity attack posture, and any claim construction outcomes. The case caption does not provide enough for a quantified assessment.

Scorecard for patent-estate strength (what to compute from docket + patent texts)

• Count of asserted patents and claims
• Proximity to expiration (days/months)
• Number of surviving asserted claims at summary judgment
• Whether the brand controls the core compound claims
• Prior art intensity and obviousness record
• Unexpired exclusivity coverage

---

What settlement terms typically resolve cases like this and what should be checked in this docket?

Featured snippet (answer): Hatch-Waxman settlements often resolve with a dismissal tied to launch timing and sometimes a license. The actual terms for 1:14-cv-01844 must be read from the docket entries.

Terms to verify

• Date of stipulation of dismissal
• Whether dismissal is with or without prejudice
• Carve-outs (e.g., method-of-use label language)
• Payment structure (if any)
• Trigger events tied to FDA approval milestones

---

How does Sanofi’s case against Sun Pharma Global FZE compare with similar brand-generic fights?

Featured snippet (answer): Procedurally, cases in this template usually follow the same Hatch-Waxman pattern: asserted Orange Book patents, ANDA paragraph IV certification, claim construction and summary judgment, followed by settlement or judgment. Comparative valuation depends on the asserted patent types and the court’s construction outcomes.

Competitive landscape angle

Sun Pharma’s strategy in multi-patent disputes often includes:

• Narrow label design to avoid method-of-use infringement
• Process or formulation changes to reduce literal or DOE (doctrine of equivalents) risk
• Validity challenges to invalidate the most blocking patents

---

Key Takeaways

• 1:14-cv-01844 is a Hatch-Waxman style infringement dispute: Sanofi vs Sun Pharma Global FZE, tied to Orange Book-listed patents and Sun’s generic ANDA entry strategy.
• The specific asserted patents, claim lists, court rulings, and settlement terms cannot be determined from the case identifier alone.
• The litigation’s business impact is driven by: (1) which patents are asserted, (2) claim construction results, (3) validity outcomes, and (4) whether a settlement sets launch timing or covenants not to sue.

---

FAQs

1. Does a stipulation of dismissal in a Hatch-Waxman case mean the brand’s patents were upheld?
2. How do method-of-use patents affect label design and “at-risk” launch for generics?
3. What docket entries indicate whether Sun’s ANDA received a 30-month stay?
4. Can a generic launch before patent expiration if it designs around a formulation patent?
5. What information in the complaint confirms the exact Orange Book patents asserted?

---

References (APA)

1. US District Court docket for Sanofi v. Sun Pharma Global FZE, 1:14-cv-01844.